Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Etrasimod Versus Mesalazine in Chinese Adult Patients With Active Ulcerative Colitis
NCT07782242Phase 4Not yet recruiting
- Sponsor
- Sir Run-Run Shaw Hospital
- Start
- Jul 2026
- Primary completion
- Jun 2027
01
Overview
Phase 4, randomised, open-label trial of etrasimod in ulcerative colitis (UC) (2 arms), sponsored by Sir Run-Run Shaw Hospital. Primary endpoint: Percentage of participants achieving clinical remission at 24 weeks. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
etrasimod
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT07782242.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07782242.